A Phase 2, Open Label Extension Study To Investigate The Long Term Safety And Tolerability Of Pf-06649751 In Subjects With Motor Fluctuations Due To Parkinson's Disease
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Tavapadon (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Dec 2017 Status changed from active, no longer recruiting to discontinued.
- 23 Nov 2017 This trial has been discontinued in Spain (End date: 2017-09-22).
- 09 Nov 2017 This trial has been discontinued in Germany.